Teleflex reduced its 2026 pro forma adjusted constant currency revenue growth guidance to 3.5%–4.5% from 4.5%–5.5%, citing a slower-than-expected integration of the vascular intervention business. The interventional segment saw revenue decline 1% in the second quarter, falling short of expectations due to ongoing order-to-cash transitions, distributor changes, and sales force realignment. Despite the headwinds, the company delivered better-than-expected revenue, adjusted margins, and adjusted EPS in Q2, with strength in vascular and surgical units. Teleflex also closed its OEM divestiture, generating approximately $1.5 billion in proceeds to fund debt reduction and share repurchases, including a $250 million buyback completed in the quarter and an additional $250 million accelerated share repurchase set to begin on August 7, 2026. The company raised its full-year adjusted EPS guidance to $6.90–$7.20, reflecting the benefit of share repurchases and lower net interest expense. New CEO Jason Weidman, who brings 20 years of interventional experience, expressed strong conviction in the long-term prospects of the interventional business and expects to provide more details on his strategic vision by the next earnings call.
Teleflex IncorporatedCompany cut 2026 revenue growth guidance due to slower integration of vascular intervention business.
